Anbio Biotechnology (NNNN)

Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11.76	9.69	7.1	4.18
Short-Term Investments	-	-	1.57	-
Cash & Short-Term Investments	11.76	9.69	8.67	4.18
Cash Growth	21.40%	11.75%	107.33%	-
Receivables	1.06	1.88	-	0.72
Inventory	-	-	0.35	-
Prepaid Expenses	5.71	4.17	4.92	0.02
Other Current Assets	0	0	0	0
Total Current Assets	18.53	15.75	13.94	4.92
Property, Plant & Equipment	-	-	0.01	-
Long-Term Deferred Charges	0.39	0.04	-	-
Other Long-Term Assets	-	0.02	0	-
Total Assets	18.92	15.81	13.96	4.92
Accounts Payable	1.63	0.83	1.41	1.89
Accrued Expenses	-	0.13	-	-
Other Current Liabilities	0.1	0.03	0	0.49
Total Current Liabilities	1.73	0.99	1.41	2.38
Total Liabilities	1.73	0.99	1.41	2.38
Common Stock	0.01	0.01	-	-
Additional Paid-In Capital	0	0	-	-
Retained Earnings	17.17	14.8	12.55	2.54
Shareholders' Equity	17.19	14.82	12.55	2.54
Total Liabilities & Equity	18.92	15.81	13.96	4.92
Net Cash (Debt)	11.76	9.69	8.67	4.18
Net Cash Growth	21.40%	11.75%	107.33%	-
Net Cash Per Share	0.28	0.45	-	-
Filing Date Shares Outstanding	43.89	42.29	-	-
Total Common Shares Outstanding	42.29	42.29	-	-
Working Capital	16.8	14.76	12.53	2.54
Book Value Per Share	0.41	0.35	-	-
Tangible Book Value	17.19	14.82	12.55	2.54
Tangible Book Value Per Share	0.41	0.35	-	-

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q